Macrophage involvement in human immunodeficiency virus (HIV) pathobiology has received increased interest during recent years. Macrophages are known to harbor latent HIV, thereby hampering complete disease eradication by current therapies; consequently, macrophages are potential targets for novel anti-HIV treatments [1] .
Mucosa-patrolling macrophages and dendritic cells are among the first to encounter HIV at the time of infection, and are involved in the initial anti-HIV immune reaction [2] . However, macrophages are also able to transmit HIV to recruited T cells, thus disseminating the virus [2, 3] . One mechanism by which HIV-1 binds to macrophages is by envelope glycoprotein 120 interaction with the macrophage mannose receptor (MR/ CD206) [3] . Furthermore, blocking the HIV type 1 (HIV-1)-CD206 interaction could reduce subsequent transfer of HIV-1 from macrophages to T cells [4] .
The relatively macrophage-specific receptor CD206 and the hemoglobin-haptoglobin scavenger receptor CD163 are commonly used makers of macrophages both in vivo and in vitro. CD206 is mainly expressed by macrophages, but may be found on dendritic cells and endothelial cells [5] . Both CD206 and CD163 can be cleaved from the cell surface, resulting in soluble proteins (soluble CD206 [sCD206/sMR] and soluble CD163 [sCD163] ) that can be detected in blood samples [5, 6] .
The macrophage activation biomarker sCD163 has been extensively investigated in patients with HIV-1 and, to a lesser extent, in patients with HIV type 2 (HIV-2) infection [7] . Plasma sCD163 was positively associated with HIV-1 plasma RNA levels, whereas an inverse association with CD4 T-cell counts was seen [8] . We recently found that sCD163 levels decreased significantly upon antiretroviral treatment (ART) in HIV-1, but not in patients with HIV-2 or dual infection [7] .
Evidence suggests that CD206 and CD163 are differentially expressed on macrophages [9] . CD206 is a specific marker of perivascular macrophages (initial target cells of HIV within the brain), and the expression decreased in rhesus monkeys upon simian immunodeficiency virus infection [10] . Therefore, and since CD206 may be involved in HIV entry into macrophages, sCD206 could be a novel biomarker in HIV, and may improve our understanding of the importance of macrophages in HIV pathobiology. As a biomarker, sCD206 may prove useful in a therapeutic setting with macrophage-specific drug delivery obtained by targeting CD206, as suggested recently [11, 12] .
In this study, we investigated sCD206 levels in HIV-1-infected, HIV-2-infected, and HIV-1/2 dually infected patients to compare biomarker levels between different HIV types, to investigate changes during therapy, and to explore associations with patient characteristics and known prognostic factors.
METHODS

Study Population
All patients were included in the Bissau HIV Cohort [13] at the Hospital Nacional Simão Mendes, Bissau, Guinea-Bissau, from 2007 to 2012, as described in our recent report using the same cohort [7] . In brief, 75% were female, with a median age of 37 years (29-45 years). "Baseline" is the first sample collected after diagnosis, and "follow-up" is the first sample taken >6 months after diagnosis. See Supplementary Data for further details.
Laboratory Methods
Peripheral blood levels of CD4 + T cells (cells/μL) were measured in Bissau, and plasma concentrations of C-reactive protein (CRP.L3 assay, Roche Diagnostics) and sCD163 (in-house assay) were measured as described previously [7] . Peripheral blood plasma levels of sCD206 were determined using an in-house enzyme-linked immunosorbent assay at the Department of Clinical Biochemistry, Aarhus University Hospital, Denmark, as described previously [5] . See the Supplementary Data for further details, including information on HIV-type testing.
Statistical Analyses
Concentrations of sCD206 are given in milligrams per liter, as median with interquartile range (IQR).
All statistical analyses were performed using Stata 14.2 software for Mac (StataCorp). Graphs were made using Prism 5 for Mac (GraphPad Software). Normal distribution of data was evaluated using Q-Q plots, and appropriate transformation was applied when needed before using parametric statistics. Differences between groups were tested using analysis of variance and t test, as well as multivariable linear regression analyses. Associations between parameters were investigated using linear regression and Pearson correlation analyses.
RESULTS
Baseline characteristics of the 212 included HIV-infected patients are described in detail in our previous report using the same cohort of patients [7] . In brief, the HIV types were 51.4% HIV-1 (n = 109), 26.4% HIV-2 (n = 56), and 22.2% HIV-1/2 dual infection (n = 47).
Plasma Levels of sCD206 at Diagnosis Is Unaffected by HIV Type
Peripheral blood plasma concentrations of sCD206 in patients with HIV-1, HIV-2, and dual infection are shown in Figure 1 and Supplementary Table 1-at the time of HIV diagnosis and at follow-up (6-24 months), with or without ART. Baseline plasma levels of sCD206 (median and IQR) were 0.33 mg/L (0.23-0.47) for HIV-1, 0.30 mg/L (0.23-0.43) for HIV-2, and 0.32 mg/L (0.22-0.41) for HIV-1/2. There was no difference between the 3 groups at baseline (P = .28). This was also the case after adjusting for CD4 cell count and patient age at diagnosis (by multivariable regression, P = .08). The majority of patients had sCD206 levels within the established reference range (0.1-0.43 mg/L in healthy Danish subjects); 27.8% had elevated sCD206 levels at diagnosis.
Baseline Associations of sCD206 With HIV-Related and Inflammatory
Parameters
Correlation analysis showed a tendency toward negative association between sCD206 and CD4 count (P = .09; Supplementary  Figure 2 ). To explore associations with clinically relevant parameters (HIV type, age, body mass index [BMI], sex, CRP), we displayed sCD206 levels in the patients stratified by CD4 counts (Supplementary Table 2 ). Patients with CD4 count ≤200 cells/μL tended to have higher sCD206 levels compared to patients with higher CD4 counts (P = .06). Furthermore, levels of sCD206 were higher in patients with CRP levels >8 mg/L (all P < .05), and also tended to be higher in patients with BMI ≤18.5 kg/m 2 , especially for patients with CD4 count <200 cells/ μL (all P < .05). In general, however, differences were small. We found a positive correlation between sCD206 and levels of sCD163 (P < .001) and CRP (P < .001; Supplementary Figure 2) . Finally, Table 1 shows univariable and multivariable regression analyses of sCD206 vs various HIV-related clinicopathological and inflammatory parameters. The only parameters associated with high sCD206 in both univariable and multivariable analyses were low BMI and high CRP.
Treatment With ART Decreases sCD206 in Both HIV-1-and HIV-2-Infected
Patients
For patients followed without ART, there were no statistically significant changes in sCD206 levels between diagnosis and follow-up. In this patient group, there was also no change in CRP levels between diagnosis and follow-up, whereas CD4 cell counts decreased for all 3 HIV subgroups (see Supplementary  Figure 3 for CD4 cell count data).
For patients started on ART, sCD206 levels decreased between diagnosis and follow-up in both HIV-1-and HIV-2-infected patients (P < .0001), but not in the HIV-1/2 dually infected (P = .35). The decrease in sCD206 was larger in HIV-1 vs HIV-1/2 (P = .007) and in HIV-2 vs HIV-1/2 (P = .03), whereas there was no difference in sCD206 changes between HIV-1-vs HIV-2-infected patients (P = .87).
In the ART-receiving patients, changes in CRP levels showed a pattern similar to sCD206, with decreased CRP levels at follow-up for HIV-1 (P = .02) and HIV-2 (P < .0001), but not for HIV-1/2-infected patients (P = .39). Furthermore, as expected, CD4 counts increased during ART in all 3 patient groups (P < .0001; Supplementary Figure 3) .
Decrease in sCD206 on ART Is Associated With Increased CD4 Cell Counts
To investigate whether the decrease in sCD206 levels during ART was related to disease progression, we examined the association between the relative changes in CD4 count and sCD206. The median relative decrease in sCD206 levels upon ART (for all treated patients) was -25.7% (IQR, -43.3% to -6.1%), and the median increase in CD4 count was 107.7% (IQR, 48.1%-263.3%).
Interestingly, there was a negative association between these relative changes (decreased sCD206 with increased CD4 counts; n = 89; R = 0.26, P = .01). Contrarily, no such association was seen between changes in CD4 counts and changes in CRP, a more general marker of inflammation (P = .44).
Lastly, changes in sCD206 were positively associated with changes in levels of the macrophage activation biomarker sCD163 (n = 89; R = 0.52, P < .001). In contrast, there was no association between the relative changes in sCD206 levels and the changes in CRP (P = .56).
DISCUSSION
Macrophages are important in HIV pathobiology, and peripheral blood levels of the well-described macrophage-derived biomarker sCD163 has been associated with HIV RNA levels [8] and CD4 count [7] , with HIV comorbidities [6] , and with mortality [14] . The vast majority of these results were obtained in studies on HIV-1-infected individuals.
Here, we present the first data on the novel macrophage activation biomarker sCD206 (soluble macrophage mannose receptor/sMR) in both HIV-1-, HIV-2-, and HIV-1/2 dually infected patients from the Bissau HIV Cohort. In Guinea-Bissau, healthcare resources are limited. Thus, quantification of inflammatory markers and HIV RNA is not available, and there was insufficient material for subsequent RNA measurements, which is a limitation. Furthermore, it would have been interesting to compare sCD206 levels in HIV-infected patients with matched healthy individuals from Guinea-Bissau. However, such samples from healthy volunteers were not available. Last, we did not have data available to investigate the value of sCD206 as a prognostic marker in the present cohort. However, there was a significant association between high sCD206 and low BMI (a well-known poor prognostic factor in HIV). Thus, sCD206 should be investigated further, as a prognostic biomarker in HIV.
Whereas HIV-1 is pandemic, HIV-2 is mainly found in West Africa. On average, HIV-2 is less transmissible, associated with a lower viral load and mortality rate, and with a large proportion of long-term nonprogressors compared to HIV-1. However, among patients with clinical progression, the pathological mechanisms seem to resemble those of HIV-1 [7] . Importantly, the pathology of HIV-2 has not been investigated as thoroughly as for HIV-1, and not much is known about differences between HIV-1 and HIV-2 regarding the impact on the host's immune system. In the present study, we analyzed samples from patients attending an HIV clinic in Guinea-Bissau, many with progressed disease. Levels of sCD206 did not differ between patients with HIV-1 vs HIV-2 vs HIV-1/2 infection at diagnosis. This result parallels previous studies showing similar levels of myeloid cell-related inflammation among ART-naive HIV-1-and HIV-2-infected patients [15] , and similar levels of circulating sCD163 in HIV-1-, HIV-2-, and HIV-1/2 dually infected patients [7] . For patients on ART, levels of sCD206 decreased significantly during treatment in both HIV-1-and HIV-2-, but not in HIV-1/2 dually infected patients. This result differs from our recent observation that sCD163 decreased significantly in HIV-1, but not in HIV-2 or dually infected patients during ART [7] . This result may indicate a difference in HIV-1 vs HIV-2 influence on myeloid cells with differential expression of CD163 and CD206, for example, CD206 + CD163
+ vs CD206 -CD163 + perivascular macrophages that are targets of HIV in the brain [10] or interleukin 4-stimulated (CD206 high ) vs interleukin 10-stimulated (CD163 high ) macrophages [9] . However, adequate investigations in vivo remain, and thus further studies are needed.
There was a strong correlation between sCD206 and sCD163 levels at diagnosis. This was partly expected since CD206 and CD163 are both markers of alternatively activated macrophages, and associations between the 2 have been demonstrated in other diseases, including patients with malignant disease [5] .
There was an association between the increase in CD4 counts and the decrease in sCD206 levels seen upon ART, whereas there was no such association between changes in CD4 counts and changes in levels of CRP (a general inflammation marker). This indicates that sCD206 is not a bystander marker for changes in general inflammation levels in HIV patients, but does reflect disease-associated regulation of CD206-expressing macrophages.
Lastly, macrophages may be future therapeutic targets in patients with HIV [11] , and CD206 is a potential gateway for such drug delivery [12] . Thus, biomarkers of macrophage activation including sCD206 could be important when using such therapeutic strategies, which should be investigated in future studies.
CONCLUSIONS
We present the first data on sCD206, a novel biomarker of macrophage-related inflammation in HIV. Baseline sCD206 levels were similar between HIV types, and were unchanged at follow-up without treatment. However, on ART, sCD206 decreased in both HIV-1-and HIV-2-infected patients, but not in HIV-1/2 dually infected patients. Thus, sCD206 may add additional information about macrophage activation in HIV patients, especially for patients on ART, and this biomarker should be investigated further.
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